SEC Form 4 · accession 0001349297-26-000004
Roivant Sciences Ltd. · ROIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Meghan Fitzgerald
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 7:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001635088
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jun 30, 2026 | M | 10,000 | $8.80 | A | 52,963 | D | |
| Common Shares | Jun 30, 2026 | S | 10,000 | $34.90 | D | 42,963 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.80 | Jun 30, 2026 | M | 10,000 | D | — | Apr 19, 2033 | Common Stock | 10,000 | 38,578 | D |
Explanation of responses
- F1Award of stock options to purchase Common Shares that is fully vested.